Sonnet BioTherapeutics Holdings, Inc. announced the adjournment of its special meeting of stockholders to provide additional time for voting on the proposed business combination.
More than 95% of the shares voted on the proposal to approve the Business Combination have been in favor.
The Board of Directors believes all proposals in the proxy statement are advisable for the Company's stockholders.
Voting Results
More than 95% of the voted shares support the Business Combination proposal.
Listing Approval
HSI's shares have been approved for listing on Nasdaq.
Technology Focus
Sonnet BioTherapeutics focuses on oncology with its proprietary FHAB technology for biologic drugs.
- The delay in the meeting allows time to gather additional votes for transaction approval.
- Positive sentiment from stockholders with over 95% in favor of the Business Combination proposal.
Sonnet BioTherapeutics remains focused on finalizing the Business Combination with Hyperliquid Strategies Inc and Rorschach I LLC, aiming to enhance opportunities in the Hyperliquid blockchain.